# A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

> **NCT07216703** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1023 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Sacituzumab Tirumotecan
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Rescue Medications

## Key facts

- **NCT ID:** NCT07216703
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-19
- **Primary completion:** 2031-10-29
- **Final completion:** 2031-10-29
- **Target enrollment:** 1023 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07216703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07216703, "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT07216703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*